Mode
Text Size
Log in / Sign up

Narrative review of Citri Reticulatae Pericarpium flavonoids in lung cancer microenvironment modulationCitrus Flavonoids May Help Remodel Tumors And Boost Immune Therapy

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that CRP flavonoids show potential in modulating lung cancer microenvironments, but clinical translation remains limited by contradictory evidence.

This narrative review explores the potential of flavonoid components isolated from Citri Reticulatae Pericarpium (CRP), such as nobiletin, hesperidin, and tangeretin, to modulate the lung cancer tumor microenvironment (TME). The authors synthesize various molecular mechanisms, including the regulation of oxidative stress-inflammation homeostasis, lipid metabolic reprogramming, induction of pyroptosis, and inhibition of epithelial-mesenchymal transition (EMT).

Beyond these pathways, the review identifies the modulation of ferroptosis and the cGAS-STING pathway as emerging targets in lung cancer models. The authors also discuss the potential for these flavonoids to suppress tumor angiogenesis and enhance the efficacy of immune checkpoint inhibitors (ICI).

However, the authors note significant limitations in the current literature, including contradictory findings, context-dependent effects, and methodological limitations in existing studies. They also highlight substantial clinical translation bottlenecks that must be addressed.

While this review provides a theoretical foundation for developing anti-lung cancer drugs from CRP flavonoids, the findings are based on a review of literature and do not establish clinical causality in humans. The evidence presented focuses on molecular mechanisms rather than clinical outcomes.

Lung cancer kills more people than any other cancer type around the world. This grim fact drives scientists to search for new ways to stop the disease. They are looking at the space right next to the tumor. This area is called the tumor microenvironment.

Doctors have long known that this space helps cancer grow. It acts like a protective shield for the malignant cells. The cells inside this shield become resistant to drugs and immune attacks.

But the old way of thinking focused only on killing the cancer cell directly. This approach often failed because the shield protected the tumor. Now researchers are trying to change the environment instead. They want to remove the shield so the immune system can attack.

Citrus fruits contain powerful plant chemicals called flavonoids. These include nobiletin, hesperidin, and tangeretin. They are found in the peel of oranges and tangerines. Scientists have found these compounds can change how the tumor behaves.

Think of the tumor like a factory. The factory needs specific parts to run. Flavonoids act like a wrench that jams the gears. They stop the factory from making new blood vessels. They also stop the cells from changing into a slippery form that spreads easily.

The study reviewed many papers from 2016 to 2026. It looked at how these chemicals work in the lab. The researchers found that flavonoids fix problems with fat metabolism. They also reduce the inflammation that fuels cancer growth.

One key finding is about a process called pyroptosis. This is a type of cell death that helps the body fight infection. Flavonoids can trigger this death in cancer cells. This makes the tumor weaker and easier to destroy.

Another important target is the cGAS-STING pathway. This is a system that alerts the immune system to danger. Flavonoids help turn this alarm system on. This allows immune cells to find and kill the cancer.

This doesn't mean this treatment is available yet.

The review also looked at how these compounds work with immune checkpoint inhibitors. These are drugs that release the brakes on the immune system. Flavonoids seem to make these drugs work much better. They help the immune system stay active longer.

However, there is a catch. Most of the data comes from mice and cell cultures. We do not know if this works exactly the same in humans. The human body is much more complex than a petri dish.

Scientists are now working on nano-delivery systems. These are tiny vehicles that carry the flavonoids to the tumor. This ensures the drug reaches the right place without harming healthy tissue. It also helps the body absorb the compound better.

The research highlights several gaps in current knowledge. Some studies show different results depending on the type of cancer. This suggests the effect depends on the specific patient and tumor. More research is needed to understand these differences.

The path to approval will take time. Clinical trials must prove safety and effectiveness in people. This process can take years before a new drug reaches the pharmacy. Patients should talk to their doctors about current options.

Future studies will focus on large groups of people. They will test if the citrus compounds work in real life. The goal is to create a new class of lung cancer drugs. These drugs would use natural compounds to fight the disease.

The potential benefits are huge for patients worldwide. Lung cancer is a leading cause of death. Finding a way to remodel the tumor could save many lives. It offers hope for those who have run out of options.

Researchers will continue to explore the chemistry of citrus peels. They will look for the best combinations of flavonoids. The aim is to create a safe and effective treatment. This work builds on a foundation of careful scientific review.

The field of cancer research is moving fast. New targets like ferroptosis are opening new doors. Flavonoids may be the key to unlocking these doors. They offer a natural way to support the body's own defenses.

Patients should not stop their current treatment without advice. But they can ask their doctor about clinical trials. Some trials may be testing these compounds soon. Staying informed helps patients make better choices for their health.

The journey from lab to clinic is long but necessary. It ensures that new treatments are safe and effective. This careful process protects patients from unproven therapies. It also builds trust in medical science.

Citrus fruits are common in many diets. The peel is often thrown away during cooking. This review suggests using the peel for medicine. It turns waste into a potential weapon against cancer. This is a promising direction for future research.

The next steps involve more testing in humans. Scientists will monitor patients closely during trials. They will look for side effects and benefits. The data will guide the development of new drugs.

This research provides a solid theoretical foundation for new drugs. It also identifies the bottlenecks that slow progress. Understanding these gaps helps scientists plan better experiments. It ensures resources are used wisely in the fight against cancer.

The story of citrus flavonoids is just beginning. It shows how nature can help us fight disease. With more study, these compounds could become standard care. They represent a new hope for lung cancer patients everywhere.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
Malignant lung tumors are the leading cause of cancer-related mortality worldwide, and therefore remodeling of the tumor microenvironment (TME) has become an important strategy to overcome anti-tumor therapy resistance in lung cancer. Flavonoid components isolated from Citri Reticulatae Pericarpium (CRP), such as nobiletin, hesperidin, and tangeretin, have been shown to modulate the lung cancer TME in a highly relevant manner. The present narrative review collected literature from the PubMed, Web of Science, Embase, CNKI, and Wanfang databases between 2016 and 2026, and hence discussed the molecular mechanisms by which CRP flavonoids reshape the lung cancer TME, namely their regulation of oxidative stress-inflammation homeostasis, correction of lipid metabolic reprogramming, induction of pyroptosis, and inhibition of epithelial-mesenchymal transition. Discussion of the role of EMT and tumor angiogenesis suppression were also presented. Then evidence regarding the modulation of emerging targets was introduced, namely ferroptosis and the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway, which are both promising targets in lung cancer models. Translational prospects of CRP flavonoids were led to enhancing immune checkpoint inhibitor (ICI) efficacy and developing nano-delivery systems. The article first outlined the fundamental barriers, then gave a very systematic and critical review of the contradictory findings, context-dependent effects, and methodological limitations in the existing literature; and then pointed out the gaps in frontier research. Therefore, it provides an excellent theoretical foundation for the research and development of anti-lung cancer drugs from CRP flavonoids, while also objectively identifying the current knowledge gaps and clinical translation bottlenecks.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.